质量水平
检测方案
≥98% (HPLC)
形式
powder
颜色
white to beige
溶解性
DMSO: 20 mg/mL, clear
储存温度
room temp
InChI
1S/C21H12ClF5N2/c22-18-10-15(24)9-6-13(18)11-29-20(12-4-7-14(23)8-5-12)16-2-1-3-17(19(16)28-29)21(25,26)27/h1-10H,11H2
InChI key
KYWWJENKIMRJBI-UHFFFAOYSA-N
生化/生理作用
WAY-252623 (LXR623) is an orally available, potent and highly selective Liver X receptors (LXRs) agonist that significantly reduced total and LDL-cholesterol. WAY-252623 reduces lesion progression in the murine LDLR(-/-) atherosclerosis model.
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
Chiara Giannarelli et al.
European heart journal, 33(2), 264-273 (2011-05-25)
The aim of this study was to investigate the effects of liver X receptors (LXRs)-β preferential activation by LXR-623 (WAY-252623), a novel LXRs agonist, on plaque progression/regression in a rabbit model of advanced atherosclerosis. Advanced atherosclerosis was induced in New
Weijun Wan et al.
Cell death & disease, 10(3), 248-248 (2019-03-15)
LXR-623 (WAY-252623), a liver X receptor agonist, reduces atherosclerotic plaque progression and remarkably inhibits the proliferation of glioblastoma cells, owing to its brain-penetrant ability. However, the role of LXR-623 against the proliferation of other cancer cells and the underlying mechanism
Chiara Giannarelli et al.
European heart journal, 33(2), 264-273 (2011-05-25)
The aim of this study was to investigate the effects of liver X receptors (LXRs)-β preferential activation by LXR-623 (WAY-252623), a novel LXRs agonist, on plaque progression/regression in a rabbit model of advanced atherosclerosis. Advanced atherosclerosis was induced in New
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门